| 000 | 01761 a2200493 4500 | ||
|---|---|---|---|
| 005 | 20250514070322.0 | ||
| 264 | 0 | _c20030822 | |
| 008 | 200308s 0 0 eng d | ||
| 022 | _a1466-4860 | ||
| 024 | 7 |
_a10.1038/sj.thj.6200250 _2doi |
|
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aKiladjian, Jean-Jacques | |
| 245 | 0 | 0 |
_aLong-term outcomes of polycythemia vera patients treated with pipobroman as initial therapy. _h[electronic resource] |
| 260 |
_bThe hematology journal : the official journal of the European Haematology Association _c2003 |
||
| 300 |
_a198-207 p. _bdigital |
||
| 500 | _aPublication Type: Clinical Trial; Journal Article; Multicenter Study | ||
| 650 | 0 | 4 | _aActuarial Analysis |
| 650 | 0 | 4 | _aAdult |
| 650 | 0 | 4 | _aAged |
| 650 | 0 | 4 | _aAged, 80 and over |
| 650 | 0 | 4 |
_aAntineoplastic Agents, Alkylating _xadministration & dosage |
| 650 | 0 | 4 | _aCause of Death |
| 650 | 0 | 4 | _aDisease Progression |
| 650 | 0 | 4 | _aFemale |
| 650 | 0 | 4 |
_aHematologic Diseases _xetiology |
| 650 | 0 | 4 | _aHumans |
| 650 | 0 | 4 |
_aLeukemia _xetiology |
| 650 | 0 | 4 | _aMale |
| 650 | 0 | 4 | _aMiddle Aged |
| 650 | 0 | 4 |
_aNeoplasms _xetiology |
| 650 | 0 | 4 |
_aPipobroman _xadministration & dosage |
| 650 | 0 | 4 |
_aPolycythemia Vera _xcomplications |
| 650 | 0 | 4 |
_aPrimary Myelofibrosis _xetiology |
| 650 | 0 | 4 | _aRisk Factors |
| 650 | 0 | 4 | _aSurvival Analysis |
| 650 | 0 | 4 | _aThrombosis |
| 650 | 0 | 4 | _aTreatment Outcome |
| 700 | 1 | _aGardin, Claude | |
| 700 | 1 | _aRenoux, Michel | |
| 700 | 1 | _aBruno, Franck | |
| 700 | 1 | _aBernard, Jean-François | |
| 773 | 0 |
_tThe hematology journal : the official journal of the European Haematology Association _gvol. 4 _gno. 3 _gp. 198-207 |
|
| 856 | 4 | 0 |
_uhttps://doi.org/10.1038/sj.thj.6200250 _zAvailable from publisher's website |
| 999 |
_c12550935 _d12550935 |
||